Search results for: Multi-Indication Medicines
Filter search results
Projecting Expenditure on Medicines in the NHS
4 January 2013
…scrutiny in efforts to manage costs. Forecasting spending on medicines can be useful… Medicines account for less than 10% of total NHS expenditure in the UK. Because spending on medicines…
The Impact of New Medicines in the NHS: 70 Years of Innovation
1 August 2018
…from new medicines. Their role should be considered in the use of medicines in the NHS over the next 70 years and for new medicines currently in the development pipeline….
Valuing Orphan Medicines Using Multi-Criteria Decision Analysis
7 May 2013
…medicines are concerned. Policy makers and payers continue in seek improvements in approaches to determining the value of medicines. The move towards “value based pricing” in the UK is just…
The Expanding Value Footprint of Oncology Treatments
13 May 2014
…drugs on the market for eight years or more are likely to have been approved for additional indications. New indications, for example, may be for use in a different cancer,…
Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
1 December 2017
…and made mandatory for orphan and oncology medicines. We analysed routine funding in the NHS for new medicines recently authorised via the centralised procedure with a particular focus on oncology…
The Spanish Medicines Market Today
9 February 2011
…medicines whose retail price is less than €3.12. Expected savings from these cuts are €169m. In June 2010, new rebates were announced affecting only patented medicines reimbursed under the NHS….
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
…to innovative medicines across the European Union (EU). Since then the scope of authorisation via the centralised procedure has been broadened and made mandatory for orphan and oncology medicines. We…
OHE at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare October, 2018
5 November 2018
…presented on Indication Based Pricing: A better way to value drugs? setting out the arguments for and against differential pricing by indication. This built on work from an OHE consulting…
Reflections from Adrian Towse on decades of HEOR research and impact
11 November 2025
…for New Medicines which accepts the case for indication-specific pricing in circumstances where a “uniform price across all indications, could make it commercially unviable for companies to launch new indications” I…